Menu

AACR Q&A: Elaine Mardis

The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.

Apr 18, 2016
The Scientist Staff

COURTESY OF ELAINE MARDIS

The American Association for Cancer Research (AACR) annual meeting is huge—so big that it can be tough to choose which talks to attend in person (or tune in to from afar). The Scientist asked Washington University in St. Louis’s Elaine Mardis—who is on the planning committee for this year’s conference, being held in New Orleans—to share her picks of the most buzzworthy topics in cancer research today.

The Scientist: To your mind, what are some of the hottest areas of cancer research right now?

Elaine Mardis: Immunotherapy and immunogenomics, liquid biopsy-based monitoring of patient response to therapy, [and] clinical genomic assays to identify therapeutic targets.

TS:  What are you presenting at AACR this year?  

EM: I am speaking in the opening plenary about cancer genomics and its transition to aid patient care in the cancer clinic. I also am providing a wrap-up of the cancer prevention and early detection work [being] presented at the meeting this year.                

TS: What new topics are emerging that have received less attention in past conferences?

EM: Liquid biopsy and early detection of cancers. Germline contribution of cancer susceptibility mutations in patients without a family history of cancer.

TS: What talks or posters do you anticipate finding most exciting?

EM: I think the Wednesday plenary lectures on single-cell genomics and the tumor heterogeneity plenary on Tuesday will have the most exciting talks.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.